

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

REQUEST FOR ACTION

Subject: Regental Action Under the State of Michigan Conflict of Interest Statute

Action Requested: Authorize Execution of Investment Agreements Under the MINTS Program for ONL Therapeutics, Inc.

Background

In December 2011, the Board of Regents approved guidelines for the MINTS (“Michigan Investment in New Technology Startup”) program.

The proposed investment agreements (the “Agreements”) fall under the State of Michigan Conflict of Interest Statute because the listed Interested Individual is an employee of the University and has sufficient pecuniary interest in the Agreements as partial owner of the company, and/or undertakes a board role. The law permits such an agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Board of Regents.

No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreements.

If the transaction proceeds, the parties to the Agreements would include the University and the entity listed below, and the University would receive an equity interest in the entity in return for its investment(s). The Agreements would reflect typical venture capital investing documentation.

The Investment Office is seeking approval for financing agreements up to a total of \$5 million in potential investments (through one or more rounds of financing) under MINTS for the below-listed startup. It is understood that, upon approval of this item, MINTS will have no obligation to enter into the Agreements or proceed with any investment in the company.

ONL Therapeutics, Inc., founded in 2014, and headquartered in Ann Arbor, MI, is a clinical stage biopharmaceutical company focused on the development of a small molecule for the treatment of geographic atrophy associated with age-related macular degeneration and open-angle glaucoma.


Interested Individual:

David N. Zacks, M.D., Ph.D.
Medical School: Professor of Ophthalmology and Visual Sciences

We believe state law requirements have been met with the disclosure of the interest and formal appointment arrangements with the University of Michigan.

We recommend that the Board of Regents authorize execution of agreements between the University of Michigan and ONL Therapeutics, Inc., as set forth above.

Respectfully submitted,



Geoffrey S. Chatas
Executive Vice President and
Chief Financial Officer